Therapy for Multi-Drug Resistant Strep in CAP

Nurse Practitioner, Oct 2004

Levofloxacin (Levaquin) is now approved by the FDA to treat multidrug-resistant strains of Streptococcus pneumoniae in community-acquired pneumonia (CAP), in the forms of tablets, injection, and in 5% dextrose (Levaquin Injection). Levofloxacin is a product of Johnson & Johnson.

Levofloxacin is indicated for dosage once daily.The safety and efficacy of levofloxacin have not been established in pregnant women and nursing mothers, pediatrie patients, or adolescents. It is contraindicated in people hypersensitive to levofloxacin and quinolone antimicrobials. The drug should be discontinued at the first appearance of a skin rash or other sign of hypersensitivity.

Consult full product labeling for prescribing precautions.